Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab + BD in Mayo Stage III AL Amyloidosis
NCT04474938Phase 2Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- May 2021
- Primary completion
- Jun 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab in light-chain amyloidosis, sponsored by Peking Union Medical College Hospital. Status: unknown.
02
Drugs
daratumumab
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on NCT04474938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04474938.